

**CS FOR HOUSE JOINT RESOLUTION NO. 58 (HES)
IN THE LEGISLATURE OF THE STATE OF ALASKA
SEVENTEENTH LEGISLATURE - SECOND SESSION**

BY THE HOUSE HEALTH, EDUCATION AND SOCIAL SERVICES COMMITTEE

Offered: 3/18/92

Referred: Rules

Sponsor(s): REPRESENTATIVES BOYER, Brown, Finkelstein, Ulmer, Koponen

A RESOLUTION

1 Relating to the drug mifepristone (RU 486).

2 BE IT RESOLVED BY THE LEGISLATURE OF THE STATE OF ALASKA:

3 WHEREAS the antiprogesterone steroid mifepristone, known as RU 486, has been developed
4 and tested in Europe and has been approved for use in France since November 1988; and

5 WHEREAS RU 486, which is administered orally by trained physicians, is a noninvasive
6 alternative to surgical procedures to terminate a pregnancy; and

7 WHEREAS RU 486 is an effective method of terminating a pregnancy during the earliest part
8 of the term when termination can be done most safely; and

9 WHEREAS the use of medication of this nature for terminating early pregnancy constitutes a
10 potentially significant medical and public health gain in terms of efficacy, safety, ease of use, cost, and
11 privacy of the physician-patient relationship; and

12 WHEREAS the medical community has identified RU 486 as a promising treatment for other
13 conditions, including breast and brain cancer, gynecological malignancies, osteoporosis, and Cushing's
14 disease; and

15 WHEREAS the American Medical Association, the American Public Health Association, the
16 American College of Obstetricians and Gynecologists, and the American Association for the
17 Advancement of Science have formally recognized the importance of RU 486 and support testing of

1 RU 486 in the United States; and

2 **WHEREAS** the Food and Drug Administration issued an import alert against RU 486 that has
3 thwarted the availability of RU 486 for abortifacient scientific research studies in the United States;

4 **BE IT RESOLVED** that the Alaska State Legislature supports introduction of RU 486 into the
5 United States for all appropriate scientific research of its potential medical value.

6 **COPIES** of this resolution shall be sent to the Honorable Dan Quayle, Vice-President of the
7 United States and President of the U.S. Senate; the Honorable Robert C. Byrd, President Pro Tempore
8 of the U.S. Senate; the Honorable Thomas S. Foley, Speaker of the U.S. House of Representatives; the
9 Honorable George J. Mitchell, Majority Leader of the U. S. Senate; to the Honorable Ted Stevens and
10 the Honorable Frank Murkowski, U.S. Senators, and the Honorable Don Young, U.S. Representative,
11 members of the Alaska delegation in Congress; the chief executive of Roussel UCLAF, 35 Boulevard
12 des Invalides 75007, Paris, France; David A. Kessler, Commissioner, Food and Drug Administration,
13 Department of Health and Human Services; and to Dr. Theodore Mala, Commissioner, Department of
14 Health and Social Services.